alosetron has been researched along with Ischemia in 3 studies
alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.
Ischemia: A hypoperfusion of the BLOOD through an organ or tissue caused by a PATHOLOGIC CONSTRICTION or obstruction of its BLOOD VESSELS, or an absence of BLOOD CIRCULATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alosetron users did not differ from IBS patients not using alosetron in the incidence of bowel surgery or hospitalized complications of constipation; there were no cases of colonic ischemia." | 7.72 | Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. ( Alfredson, T; Cook, SF; Miller, DP; Sands, BE; Walker, AM, 2003) |
| "Alosetron is a potent and selective serotonin antagonist that recently became the first Food and Drug Administration-approved agent for diarrhea-predominant IBS." | 5.31 | Ischemic colitis during treatment with alosetron. ( Fisher, RS; Friedel, D; Thomas, R, 2001) |
| " Reports of ischaemic colitis led to restricted use of the approved drug, alosetron." | 4.84 | Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment? ( Camilleri, M, 2007) |
| "Alosetron users did not differ from IBS patients not using alosetron in the incidence of bowel surgery or hospitalized complications of constipation; there were no cases of colonic ischemia." | 3.72 | Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. ( Alfredson, T; Cook, SF; Miller, DP; Sands, BE; Walker, AM, 2003) |
| "Alosetron is a potent and selective serotonin antagonist that recently became the first Food and Drug Administration-approved agent for diarrhea-predominant IBS." | 1.31 | Ischemic colitis during treatment with alosetron. ( Fisher, RS; Friedel, D; Thomas, R, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miller, DP | 1 |
| Alfredson, T | 1 |
| Cook, SF | 1 |
| Sands, BE | 1 |
| Walker, AM | 1 |
| Camilleri, M | 1 |
| Friedel, D | 1 |
| Thomas, R | 1 |
| Fisher, RS | 1 |
1 review available for alosetron and Ischemia
| Article | Year |
|---|---|
Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?
Topics: Carbolines; Colitis; Diarrhea; Humans; Ischemia; Risk Factors; Serotonin 5-HT3 Receptor Antagonists; | 2007 |
2 other studies available for alosetron and Ischemia
| Article | Year |
|---|---|
Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.
Topics: Adolescent; Adult; Aged; Carbolines; Child; Child, Preschool; Cohort Studies; Colon; Colonic Disease | 2003 |
Ischemic colitis during treatment with alosetron.
Topics: Carbolines; Colitis; Colonic Diseases, Functional; Colonoscopy; Humans; Ischemia; Male; Middle Aged; | 2001 |